CAMP and rheumatoid arthritis: Furthermore, as a ligand of MRGPRX239, the concentration of LL-37 in the synovium of patients with RA was significantly higher than that in patients with OA (Fig. 3g), indicating MRGPRX2-mediated activation of mast cells.